Stock-Based Compensation for Quest Diagnostics (DGX)
Stock-Based Compensation for Quest Diagnostics (DGX): headline value $61.00M · YoY 0.0%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingStock-Based CompensationSwitch metric
Latest period
$61.00M
YoY change
0.0%
5Y CAGR
-1.9%
Peak year (2020)
$97.00M
Latest annual
$88.00M
Stock-Based Compensation history chart for Quest Diagnostics (DGX) from 1996 to 2025
Stock-Based Compensation history table for Quest Diagnostics (DGX) from 1996 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $88.00M | 0.0% | ||
| 2024 | $88.00M | +14.3% | ||
| 2023 | $77.00M | 0.0% | ||
| 2022 | $77.00M | -2.5% | ||
| 2021 | $79.00M | -18.6% | ||
| 2020 | $97.00M | +73.2% | ||
| 2019 | $56.00M | -8.2% | ||
| 2018 | $61.00M | -22.8% | ||
| 2017 | $79.00M | +14.5% | ||
| 2016 | $69.00M | +32.7% | ||
| 2015 | $52.00M | +2.0% | ||
| 2014 | $51.00M | +82.1% | ||
| 2013 | $28.00M | -44.3% | ||
| 2012 | $50.30M | -30.0% | ||
| 2011 | $71.90M | +33.4% | ||
| 2010 | $53.90M | -28.2% | ||
| 2009 | $75.10M | +6.4% | ||
| 2008 | $70.60M | — | ||
| 2007 | $0 | — | ||
| 2006 | $0 | — | ||
| 2005 | $0 | — | ||
| 2004 | $0 | — | ||
| 2003 | $0 | — | ||
| 2002 | $0 | — | ||
| 2001 | $0 | — | ||
| 2000 | $0 | — | ||
| 1999 | $0 | — | ||
| 1998 | $0 | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — |
Stock-Based Compensation values are taken from Quest Diagnostics's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
Quest Diagnostics (DGX) most recent annual stock-based compensation stands at $88.00M (2025) – edged up 0.0% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Quest Diagnostics stock-based compensation compounded at -1.9% per year, with a net decline across the window.
The dataset's maximum stock-based compensation sits at $97.00M (2020); the minimum reading of $0 dates to 1996.
Among 8 Healthcare peers, Quest Diagnostics (DGX) ranks 5th; the peer median for stock-based compensation is $313.00M.
Quest Diagnostics Stock-Based Compensation by Year
Quest Diagnostics Stock-Based Compensation 2025: $88.00M
Quest Diagnostics stock-based compensation in 2025 was $88.00M, edged up 0.0% from 2024.
Quest Diagnostics Stock-Based Compensation 2024: $88.00M
Quest Diagnostics stock-based compensation in 2024 was $88.00M, grew 14.3% from 2023.
Quest Diagnostics Stock-Based Compensation 2023: $77.00M
Quest Diagnostics stock-based compensation in 2023 was $77.00M, edged up 0.0% from 2022.
Quest Diagnostics Stock-Based Compensation 2022: $77.00M
Quest Diagnostics stock-based compensation in 2022 was $77.00M, edged down 2.5% below 2021.
Quest Diagnostics Stock-Based Compensation 2021: $79.00M
Quest Diagnostics stock-based compensation in 2021 was $79.00M.
See more financial history for Quest Diagnostics (DGX).
Sector peers — Stock-Based Compensation
Companies in the same sector as Quest Diagnostics, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
Frequently asked questions
What is Quest Diagnostics's stock-based compensation?
Latest reported stock-based compensation for Quest Diagnostics (DGX) is $61.00M (period ending March 31, 2026).
How has Quest Diagnostics stock-based compensation changed year-over-year?
Quest Diagnostics (DGX) stock-based compensation changed 0.0% year-over-year on the latest annual filing.
What is the long-term growth rate of Quest Diagnostics stock-based compensation?
Quest Diagnostics (DGX) stock-based compensation compound annual growth rate is -1.9% over the most recent 5 years available.
When did Quest Diagnostics stock-based compensation hit its highest annual value?
Quest Diagnostics stock-based compensation reached its highest annual value of $97.00M in 2020.
What was Quest Diagnostics stock-based compensation in 2024?
Quest Diagnostics (DGX) stock-based compensation in 2024 was $88.00M.
What was Quest Diagnostics stock-based compensation in 2025?
Quest Diagnostics (DGX) stock-based compensation in 2025 was $88.00M.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
DGX Overview
Company profile, financial tools, and key metrics
DGX Revenue Counter
Earns $357.62 every second. See per minute, hour, and day.
DGX Earnings Counter
Earns $32.47 per second net profit. See per minute, hour, and day.
DGX Economic Scale
Exceeds Monaco's GDP. Compare with world economies.
DGX What If Invested
What if you had invested $1,000? See historical returns from any date.
DGX How It Makes Money
Discover visual breakdown of $11.28B in revenue — where it comes from and where it goes.
DGX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
DGX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
DGX Daily Price Character
Steady · 50.6% historical win rate (green days). Streaks & record days.
DGX Buybacks
2.09% TTM buyback yield. Shareholder yield & SBC comparison.
DGX Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.
DGX Dividend Profile
Yield: 1.72%. Safety: 5/8. See full history.
DGX Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
DGX Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.